SuperworthBioventus EPS BVS
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 27, 2026
- $0.77
- Latest quarter, Q2 FY26
- $0.47
- +327% on a year earlier
- Fiscal year 2025
- $0.33
Bioventus' earnings per share was $0.77 over the twelve months to Jun 27, 2026.
In its latest quarter, Q2 FY26, it was $0.47, up 327% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.33 | n/a |
| FY2024 | −$0.57 | n/a |
| FY2023 | −$2.52 | n/a |
| FY2022 | −$2.58 | n/a |
| FY2021 | −$0.16 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.47 | +327% | $0.77 | |
| Q1 FY26 | $0.04 | n/a | $0.41 | |
| Q4 FY25 | $0.21 | n/a | $0.33 | |
| Q3 FY25 | $0.05 | n/a | $0.11 | |
| Q2 FY25 | $0.11 | n/a | −$0.02 | |
| Q1 FY25 | −$0.04 | n/a | −$0.53 | |
| Q4 FY24 | −$0.01 | n/a | −$0.57 | |
| Q3 FY24 | −$0.08 | n/a | −$0.66 | |
| Q2 FY24 | −$0.40 | n/a | −$0.70 | |
| Q1 FY24 | −$0.08 | n/a | −$0.36 | |
| Q4 FY23 | −$0.10 | n/a | −$2.52 | |
| Q3 FY23 | −$0.12 | n/a | −$2.94 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BVSBioventus | $0.77 | |
| CDRECadre | $0.81 | −14% a year |
| STAAStaar Surgical | $0.07 | |
| IRMDIradimed | $1.79 | +10% a year |
| EYENational Vision | $0.61 | |
| LMATLemaitre Vascular | $2.85 | +38% a year |
| INSPInspire Medical Systems | $4.62 | +166% a year |
| MOVMovado | $1.80 | +137% a year |
| UFPTUFP Technologies | $9.28 | +8% a year |
| MDXGMimedx | $0.04 | −81% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| Peer median | $1.44 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bioventus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.